CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia

CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia

Abstract Internal tandem duplication (ITD) of FMS-like tyrosine kinase 3 (FLT3) confers poor prognosis and is found in approximately 25% of cases of acute myeloid leukemia (AML). Although FLT3 inhibitors have shown clinical benefit in patients with AML harboring FLT3-ITD, the therapeutic effect is l...

Full description

Bibliographic Details
Main Authors: Sivasundaram Karnan, Ichiro Hanamura, Akinobu Ota, Souichi Takasugi, Ayano Nakamura, Miyuki Takahashi, Kaori Uchino, Satsuki Murakami, Md Wahiduzzaman, Lam Quang Vu, Md Lutfur Rahman, Muhammad Nazmul Hasan, Toshinori Hyodo, Hiroyuki Konishi, Shinobu Tsuzuki, Kazuhiro Yoshikawa, Susumu Suzuki, Ryuzo Ueda, Masayuki Ejiri, Yoshitaka Hosokawa, Akiyoshi Takami
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-021-00446-8

Internet

https://doi.org/10.1038/s41420-021-00446-8

Similar Items